GARY M. DOSIK, M.D.; JORDAN U. GUTTERMAN, M.D., F.A.C.P.; EVAN M. HERSH, M.D.; MOHAMMED AKHTAR, M.D.; TAKUO SONODA, M.D.; ROBERT G. HORN, M.D.
Because systemic intravenous immunotherapy with Corynebacterium parvum is an effective immunopotentiating and immunotherapeutic agent in animals, clinical studies of this agent have been undertaken. Toxicities in man have been noted, but most are treated symptomatically. Three patients with metastatic melanoma developed oliguria, edema, diffuse bilateral pulmonary infiltrates, azotemia, hypoalbuminemia and hypocomplementemia, while receiving intravenous C. parvum therapy. All had renal biopsies that showed a proliferative glomerulonephritis with subendothelial basement membrane deposits. Immunofluorescence showed glomerular IgG, IgA, IgM, and the C3 component of complement. A fourth patient was found in retrospective chart review of 87 patients registered on two C. parvum-containing protocols. The frequency of the complication in this group was 3/87. Renal failure resolved in all four patients spontaneously after the cessation of C. parvum immunotherapy. Serial evaluation of renal function should be carried out in all patients on systemic adjuvant immunotherapy.
Learn more about subscription options.
Register Now for a free account.
DOSIK GM, GUTTERMAN JU, HERSH EM, AKHTAR M, SONODA T, HORN RG. Nephrotoxicity from Cancer Immunotherapy. Ann Intern Med. 1978;89:41–46. doi: 10.7326/0003-4819-89-1-41
Download citation file:
Published: Ann Intern Med. 1978;89(1):41-46.
Emergency Medicine, Hematology/Oncology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only